Peer Exchange
The Pharmacy Times® Peer Exchange series is built around video panel discussions featuring some of the most recognizable names in pharmaceuticals. Each program focuses on a specific disease, condition, or therapy, and boasts energetic, moderated conversation on a variety of subjects and questions pertaining to the topic at hand.
What can we help you find?
Expert oncologists discuss the VELIA study and the new frontline PARP inhibitor treatment veliparib.
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
Expert panelists conclude their discussion with parting advice on the management of opioid-induced constipation.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
Turning toward the future management of opioid-induced constipation, the panel defined unmet needs and potential evolutions in care.
A discussion on how to bring awareness to clinicians that are not aware of the role of an oncology pharmacist.
Comprehensive insight regarding the cost and timing of peripherally acting mu-opioid receptor antagonist therapy in opioid-induced constipation.
Annette Hood, PharmD, BCACP, leads a discussion on the role of oncology pharmacists in supporting oncologists to determine the appropriate treatment plan for individuals with ovarian cancer.
Given the 3 available peripherally acting mu-opioid receptor antagonists for opioid-induced constipation, experts consider when to use a specific agent.
Considerations for the safety/efficacy profile of peripherally acting mu-opioid receptor antagonists, particularly given their administration route.
Key opinion leaders shift their attention to use of peripherally acting mu-opioid receptor antagonists in opioid-induced constipation.